Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy

Infection

Volumn 41, Issue 2, 2013, Pages 553-557

  Preiswerk, B ^a   Rudiger, A ^a   Fehr, J ^a   Corti, N ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antibiotics; Continuous renal replacement therapy; Dosing; Gram positive infection; Intensive care

Indexed keywords

DAPTOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE INFECTION; HUMAN; NONHUMAN; PATHOGEN CLEARANCE; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CRITICAL ILLNESS; DAPTOMYCIN; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS;

EID: 84879503272     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0300-3     Document Type: Article

References (25)

1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117-23.
2. Rether C, Conen A, Grossenbacher M, Albrich WC. A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia. Infection. 2011;39:583-5.
3. CUBICIN® Product information. 2010.
4. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient - a review of the literature. Eur J Clin Microbiol Infect Dis. 2011;30:603-10.
5. Kirby A, Edwards C, Broughton CM, Williams NJ. Glycopeptide and daptomycin resistance in community-associated MRSA in the UK. Infection. 2011;39:277-9.
6. Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664-5.
7. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis. 2005;41:565-6.
8. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009;9:617-24.
9. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis. 2011;52:228-34.
10. Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. Infection. 2012. [Epub ahead of print].
11. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813-8.
12. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif. 2006;24:548-54.
13. Vilay AM, Grio M, Depestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011;39:19-25.
14. Rudiger A, Rentsch K, Maggiorini M, Corti N. Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care Med. 2011;39:1243-4; author reply 1244-5.
15. Khadzhynov D, Slowinski T, Lieker I, et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther. 2011;49:656-65.
16. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318-23.
17. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245-9.
18. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799-807.
19. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-8.
20. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org. 2006.
21. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother. 2003;47:1598-603.
22. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2012;56:3174-80.
23. Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009;29:792-9.
24. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31:527-36.
25. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177-80.